Semaglutide discontinuation

Semaglutide discontinuation has been studied in 1 paper since 2026: 1 trial in people; 1 in the past year. The newest story, Oct 25, 2026: “Semaglutide benefits partly faded in HIV-associated fat buildup”.

Intervention

1 paper studies it2 findingsUpdated Oct 5, 2026

1 new paper in 30 daysSee all 1

“Discontinuation of semaglutide in PWH with lipohypertrophy resulted in partial loss of improvements in weight, adiposity, and metabolic parameters.”

Durability of Semaglutide Effects After Treatment Discontinuation in HIV-Associated Lipohypertrophy: A Randomized, Double-Blind, Placebo-Controlled Phase 2b Clinical TrialOpen forum infectious diseases2026doi:10.1093/ofid/ofag631

None of its findings points the other way.

1 lab in 1 country

Human trial1

Studies in people

1 study gave semaglutide discontinuation to people and measured what changed.

up: Increases body weight
up: Increases insulin resistance
Randomized trial108 peoplebetween weeks 32 and 56
After treatment discontinuation in people with HIV-associated lipohypertrophy
Open forum infectious diseases, Oct 5, 2026

What did studies of Semaglutide discontinuation find?

Studies of Semaglutide discontinuation measured 2 outcomes; the most studied are insulin resistance (1 study) and body weight (1).

Insulin resistance

upin humans1

1 study

Semaglutide discontinuation increases insulin resistance in humans.
“between weeks 32 and 56, accompanied by worsening glycemic indices and insulin resistance.”
Human trialafter semaglutide discontinuation in people with HIV-associated lipohypertrophybetween weeks 32 and 56
Semaglutide benefits partly faded in HIV-associated fat buildup
Open forum infectious diseasesOct 5, 2026

Body weight

upin humans1

1 study

Semaglutide discontinuation increases body weight in humans.
“Discontinuation of semaglutide in PWH with lipohypertrophy resulted in partial loss of improvements in weight, adiposity, and metabolic parameters.”
Human trialafter treatment discontinuation in people with HIV-associated lipohypertrophybetween weeks 32 and 56
Semaglutide benefits partly faded in HIV-associated fat buildup
Open forum infectious diseasesOct 5, 2026

Latest

1 paper in 12 months

Open Forum Infectious DiseasesOct 25

Semaglutide benefits partly faded in HIV-associated fat buildup

Among 108 people with HIV-associated fat buildup in a randomized trial, semaglutide recipients retained weight and waist reductions at week 56 after stopping at week 32.Among 108 people with HIV-associated fat buildup in a randomized trial, semaglutide recipients retained weight and waist reductions at week 56 after stopping at week 32.

Randomized trial · 80 peopleSemaglutide

Paper

Semaglutide discontinuation

Studies in people

What did studies of Semaglutide discontinuation find?

Latest

Semaglutide benefits partly faded in HIV-associated fat buildup

Related